# Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload

> **NCT06468423** · NA · COMPLETED · sponsor: **RESnTEC, Institute of Research** · enrollment: 142 (actual)

## Conditions studied

- Pateints of β-thalassemia Major With Iron Overload

## Interventions

- **DRUG:** Deferasirox (DFX)
- **DRUG:** Deferoxamine (DFO)

## Key facts

- **NCT ID:** NCT06468423
- **Lead sponsor:** RESnTEC, Institute of Research
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06468423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06468423, "Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06468423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*